DaVita Inc. (NYSE:DVA) Short Interest Update

DaVita Inc. (NYSE:DVA) was the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 5,010,000 shares, a decline of 5.1% from the July 31st total of 5,280,000 shares. Currently, 6.2% of the shares of the company are short sold. Based on an average daily volume of 823,800 shares, the short-interest ratio is currently 6.1 days.

Analysts Set New Price Targets

A number of research analysts recently commented on DVA shares. TD Cowen raised their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Truist Financial boosted their target price on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Tuesday, August 20th. UBS Group increased their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Finally, Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $157.00.

DaVita Trading Down 0.4 %

Shares of DVA stock opened at $151.37 on Thursday. DaVita has a 1-year low of $71.51 and a 1-year high of $156.44. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The stock has a market cap of $12.70 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 0.80 and a beta of 0.86. The stock has a 50-day moving average of $143.01 and a 200-day moving average of $138.44.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.08 EPS. On average, equities research analysts forecast that DaVita will post 9.99 earnings per share for the current year.

Insider Buying and Selling at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares in the company, valued at approximately $36,299,008.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The disclosure for this sale can be found here. Insiders have sold a total of 113,601 shares of company stock worth $17,525,449 over the last ninety days. Insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new stake in DaVita in the 2nd quarter valued at about $9,615,000. Chase Investment Counsel Corp acquired a new stake in DaVita in the second quarter valued at approximately $2,933,000. B. Riley Wealth Advisors Inc. increased its holdings in shares of DaVita by 78.9% during the second quarter. B. Riley Wealth Advisors Inc. now owns 4,130 shares of the company’s stock valued at $572,000 after acquiring an additional 1,822 shares in the last quarter. Creative Planning raised its position in shares of DaVita by 5.0% during the second quarter. Creative Planning now owns 8,297 shares of the company’s stock worth $1,150,000 after purchasing an additional 394 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of DaVita by 0.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,244 shares of the company’s stock worth $6,269,000 after purchasing an additional 150 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.